Recent research highlights the challenges of drug resistance in multiple myeloma, particularly to immunomodulatory drugs (IMiDs). Understanding genetic changes, such as those affecting cereblon, is crucial for developing more effective treatments. A novel cereblon variant has been identified in both newly diagnosed and relapsed cases, which could play a role in resistance (Zhu et al., 2025).
Therapies targeting B-cell maturation antigen (BCMA), such as antibody-drug conjugates and CAR-T cell therapies, show promise in improving patient outcomes. Additionally, advancements in diagnostic tools aim to enhance accuracy and precision in diagnosis, providing more personalized treatment strategies. These developments are crucial for improving patient outcomes in multiple myeloma.